Mr Rhys Mant

Mr Rhys Mant

Institute of Cancer and Genomic Sciences
Senior Trial Coordinator

Contact details

Address
Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT

Mr Rhys Mant is a Senior Trial Coordinator for the Tessa Jowell BRAIN MATRIX study and the ARISTOCRAT trial within the Early Drug Development Team at the Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, at the University of Birmingham.

Rhys also coordinates the PePS2 Trial and the WISTERIA trial.

Qualifications

  • MA in Medieval History, University of Birmingham, 2011
  • BA (Hons) in Medieval and Modern History, University of Birmingham, 2009

Publications

Kong, A, Kirkham, AJ, Savage, JS, Mant, R, Lax, S, Good, J, Forster, MD, Sacco, JJ, Schipani, S, Harrington, KJ, Yap, C & Mehanna, H 2024, 'Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer', BJC Reports, vol. 2, no. 1, 6. https://doi.org/10.1038/s44276-023-00026-6

Bhaskaran, D, Savage, J, Patel, A, Collinson, F, Mant, R, Boele, F, Brazil, L, Meade, S, Buckle, P, Lax, S, Billingham, L & Short, S 2024, 'A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): Protocol for a multi-centre, double-blind, placebo-controlled trial', BMC Cancer, vol. 24, 83. https://doi.org/10.1186/s12885-023-11792-4

Watts, C, Savage, J, Patel, A, Mant, R, Wykes, V, Pohl, U, Bulbeck, H, Apps, J, Sharpe, R, Thompson, G, Waldman, AD, Ansorge, O & Billingham, L 2022, 'Protocol for the Tessa Jowell BRAIN MATRIX Platform Study', BMJ open, vol. 12, no. 9, e067123. https://doi.org/10.1136/bmjopen-2022-067123

Middleton, G, Brock, K, Savage, J, Mant, R, Summers, Y, Connibear, J, Shah, R, Ottensmeier, C, Shaw, P, Lee, SM, Popat, S, Barrie, C, Barone, G & Billingham, L 2020, 'Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial', The Lancet Respiratory Medicine, vol. 8, no. 9, pp. 895-904. https://doi.org/10.1016/S2213-2600(20)30033-3

Kong, A, Good, JS, Kirkham, A, Savage, J, Mant, R, Llewellyn, L, Parish, J, Spruce, R, Forster, M, Schipani, S, Harrington, K, Sacco, JJ, Murray, P, Middleton, G, Yap, C & Mehanna, H 2020, 'Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol', BMJ open, vol. 10, no. 3, e033009. https://doi.org/10.1136/bmjopen-2019-033009